During phase II detoxification in the liver, glutathione conjugation takes place, an important phase in detoxification
SGK-1 agonists such as BN-119 and BN-201
Adashek, J
p 9.5% Baseline characteristics Average age 54 years Average BMI - 36 Average weight - 220 lbs (100 kg) Type 2 diabetes - 58% Average NAFLD activity score - 5.3 Liver fibrosis stage: F2 - 43% | F3 - 57% Randomized treatment groups Group 1 (47 patients): Tirzepatide 5 mg once weekly Group 2 (47patients): Tirzepatide 10 mg once weekly Group 3 (48 patients): Tirzepatide 15 mg once weekly Group 4 (48 patients): Placebo Therapy was initiated at 2.5 mg, and patients were titrated to their assigned dose in 2.5 mg increments every 4 weeks Resolution of MASH (defined as no steatotic liver disease [steatosis score of 0] or simple steatosis [a steatosis score of 1, 2, or 3] without steatohepatitis and an inflammation score of 0 or 1 and a ballooning score of 0), without worsening of fibrosis (defined as no increase in the fibrosis stage) at week 52 Primary outcome: Results In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis
Therefore, we examined the genes with the greatest log-fold increase in response to liraglutide treatment in cells, which encode a secreted factor
10.1001/jamasurg.2024.0111 [DOI] [PMC free article] [PubMed] [Google Scholar] 38.Maselli DB, Lee D, Bi D, Jirapinyo P, Thompson CC, Donnangelo LL et al (2024) Safe continuation of glucagon-like peptide 1 receptor agonists at endoscopy: a case series of 57 adults undergoing endoscopic sleeve gastroplasty
